Prior Authorization for Fractional Ablative Laser

Prior authorization may be required for fractional ablative laser (CPT 0479T, 0480T) when used for burn, traumatic, or post‑surgical scars. Authorization is generally considered only when documentation shows significant functional impairment (for example, restricted movement) and prior trial and failure of conventional conservative therapies (e.g., hypoallergenic paper tape, silicone gel/sheeting, pressure garments) have been attempted and documented.

• Affected codes: 0479T, 0480T
• Document trial and failure of conservative therapies (see documentation callout)

BTX‑A Prior Authorization Consideration

Botulinum toxin A (BTX‑A) injections have RCTs and meta‑analyses reporting improvements in scar width, VSS/VAS scores, and patient satisfaction; prior authorization may be considered on a case‑by‑case basis depending on plan benefits and submitted evidence.

• Evidence: multiple RCTs and meta‑analyses (e.g., Zhang 2016; Qiao 2021)
• Consider documenting scar location, prior treatments, and objective measures

Prior Authorization for AFL Procedures

Given evolving practice patterns and evidence that CO2‑AFL has been associated with reduced length of stay and anesthetic time in some series, prior authorization for ablative fractional laser (AFL) procedures may require additional clinical documentation supporting medical necessity and that conservative measures were tried.

• Document expected clinical benefit and prior conservative therapy
• Consider operative/anesthesia implications when determining authorization

Authorization Likely for Radiotherapy and HBOT

Authorization is likely for excision with adjuvant radiotherapy and for hyperbaric oxygen therapy (HBOT) when supported by clinical documentation consistent with the Clinical Policy Bulletin and plan benefits.

• Radiotherapy for chest keloids: recurrence data support use as adjuvant therapy
• HBOT: meta‑analysis suggests reduced recurrence after surgery/radiotherapy

Prior Authorization per Clinical Policy Bulletin

Coverage and prior authorization requirements are governed by this Clinical Policy Bulletin and the member's individual plan benefits. Providers should follow Aetna procedures for submitting prior authorization requests and supporting documentation.

• Follow Clinical Policy Bulletin procedures and individual plan benefits
• Prior authorization determinations depend on submitted documentation and plan terms

Prior Authorization Not Specified in This Section

This section does not specify universal prior authorization triggers for all listed interventions. Some therapies may be subject to prior authorization depending on plan benefits, coding, and whether interventions are considered experimental/ investigational for the indication.

• Not all interventions in this section have explicit prior authorization rules
• Check member's plan documents for applicability

Background Evidentiary Implications

The evidence base includes heterogeneous study designs, variable quality, and evolving literature; experimental or insufficient evidence for some therapies increases the risk of denial if clinical justification or high‑quality supporting data are not provided.

• Heterogeneity and low quality of some trials may affect authorization decisions
• Experimental/insufficient evidence treatments (see policy list) are at higher denial risk

Verapamil vs Triamcinolone Recurrence Risk

A randomized split‑scar RCT showed higher keloid recurrence with verapamil compared with intralesional triamcinolone (hazard ratio 8.44); verapamil was safe but less effective, and the trial was terminated early for inferiority. This impacts expectations for verapamil as an alternative to corticosteroids.

• Study: Danielsen et al (2016) — verapamil vs triamcinolone; higher recurrence with verapamil
• Implication: document rationale if verapamil is used instead of triamcinolone

P‑RF for Keloids Excluded in Reported Series

Patients with keloids were excluded from reported plasma radiofrequency (P‑RF) ablation series due to unsatisfactory results; P‑RF for keloids lacks supportive evidence and may be considered unsuitable or experimental for keloid treatment.

• P‑RF studies excluded keloid patients due to poor outcomes
• Treating providers should document rationale if using P‑RF in atypical cases

Experimental / Insufficient Evidence Risk

Therapies listed as experimental or investigational in this policy (e.g., adipose‑derived stem cell therapy, intralesional botulinum toxin for keloids, dermal substitutes, extracorporeal shock wave therapy) carry an increased risk of denial due to insufficient evidence; provide robust clinical justification and supporting literature if requesting coverage.

• Refer to policy's Experimental and Investigational list for non‑covered interventions
• Submit peer‑reviewed evidence if requesting exception

No Explicit Authorization or Denial Triggers

There are no explicit automatic authorization or denial triggers listed in these supplemental provider‑actions; decisions are determined by plan benefits, evidence quality, and the adequacy of submitted clinical documentation.

• Authorization decisions are individualized
• Lack of explicit triggers means documentation quality drives decisions

Suggested Clinical Documentation

Suggested clinical documentation to support prior authorization requests includes objective scar severity assessments (e.g., Vancouver Scar Scale, Manchester Scar Scale, POSAS, UNC4P), standardized pre‑ and post‑treatment photographs, description of functional impairment, dates and details of prior treatments, response to prior therapies, and proposed treatment plan (dose, frequency, and number of sessions).

• Include validated scar scores (VSS, POSAS, Manchester Scar Scale, UNC4P)
• Provide dated photos, prior treatment history, and objective measures of functional impairment
• For intralesional corticosteroids document concentration, intervals, and number of treatments

Combination, First‑Line, and Stepwise Approach / Conservative Therapies Prior to Advanced Interventions

A stepwise, combination and conservative approach is reflected in the evidence: intralesional corticosteroids (triamcinolone) are a preferred first‑line non‑surgical therapy; combination therapies (e.g., surgery plus intralesional steroid, cryosurgery plus steroid) are commonly used; and conservative measures (silicone sheeting, pressure therapy, hypoallergenic tape, onion extract) are often recommended prior to advanced interventions such as laser or surgery.

• Preferred first‑line: intralesional triamcinolone (10–40 mg/mL)
• Conservative therapies trial: silicone gel/sheeting and pressure therapy for 8–12 weeks where applicable
• Combination therapies are frequently used and supported by some studies

Provider Resources and Links

Providers may find additional resources and links on Aetna's site for policy details, glossary, mobile app, FAQs, and program provisions. Use these resources and the Clinical Policy Bulletin for guidance on benefits, submission procedures, and administrative questions.

• Aetna Clinical Policy Bulletin Notes and plan‑specific procedures
• Glossary: https://www.aetna.com/glossary.html
• Aetna Mobile App: https://www.aetna.com/individuals-families/using-your-aetna-benefits/aetna-mobile.html
• FAQs and Program Provisions available on Aetna website